Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bolt Biotherapeutics, Inc. (BOLT)
:BOLT
RESEARCH TOOLSreports
Holding BOLT?
Track your performance easily
BOLT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.48 - $1.56
Previous CloseN/A
Volume72.19K
Average Volume (3M)193.87K
Market Cap
$20.62M
Enterprise Value-$11.63M
Total Cash (Recent Filing)$13.63M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Mar 26, 2025EPS Estimate
-0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.71
Shares Outstanding38,273,003
10 Day Avg. Volume214,398
30 Day Avg. Volume193,865
Standard Deviation0.20
R-Squared0.05
Alpha-0.07
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2.11
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.56
Enterprise Value/Revenue-1.19
Enterprise Value/Gross Profit-1.48
Enterprise Value/Ebitda0.19
Forecast
1Y Price Target
$1.75Price Target Upside224.07% Upside
Rating ConsensusHold
Number of Analyst Covering3
Bolt Biotherapeutics News
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Changes and Appointments
PremiumCompany Announcements
Bolt Biotherapeutics’ Restructuring Faces Potential Setbacks: A Closer Look
PremiumCompany Announcements
Bolt Biotherapeutics Reports Q3 2024 Financial Results
PremiumCompany Announcements
Bolt Biotherapeutics Announces Board Reshuffle and New Appointment
Bulls Say, Bears Say
Bulls Say
Clinical TrialsBDC-3042 has progressed to its final Phase 1 monotherapy dose level without any observed dose-limiting toxicities, showing promising safety and effectiveness.
Financial PositionThe company has a strong financial position with $84.4 million in cash, ensuring a stable runway for operations through mid-2026.
Preclinical StudiesBDC-4182 demonstrated impressive efficacy in preclinical models and was well tolerated in non-human primates, showing potential for better performance than existing treatments.
Bears Say
Clinical TrialsThe stock is expected to remain pressured until clinical trials play out in 2025.
Financial PerformanceBolt reported 3Q24 revenue of $1.1M and EPS of ($0.40), compared to estimates of $1.7M and ($0.38), respectively.
Investment UncertaintyAnalyst maintains a Neutral rating and has no price target as more clarity on the company’s pipeline is awaited.
---
Options Prices
Currently, No data available
---
Ownership Overview
11.18%
Insiders
3.95% Mutual Funds
42.35% Other Institutional Investors
39.29% Public Companies and Individual Investors
BOLT FAQ
What was Bolt Biotherapeutics, Inc.’s price range in the past 12 months?
Bolt Biotherapeutics, Inc. lowest stock price was $0.47 and its highest was $1.56 in the past 12 months.
What is Bolt Biotherapeutics, Inc.’s market cap?
Bolt Biotherapeutics, Inc.’s market cap is $20.62M.
When is Bolt Biotherapeutics, Inc.’s upcoming earnings report date?
Bolt Biotherapeutics, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 72 days.
How were Bolt Biotherapeutics, Inc.’s earnings last quarter?
Bolt Biotherapeutics, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.34 by -$0.06.
Is Bolt Biotherapeutics, Inc. overvalued?
According to Wall Street analysts Bolt Biotherapeutics, Inc.’s price is currently Undervalued.
Does Bolt Biotherapeutics, Inc. pay dividends?
Bolt Biotherapeutics, Inc. does not currently pay dividends.
What is Bolt Biotherapeutics, Inc.’s EPS estimate?
Bolt Biotherapeutics, Inc.’s EPS estimate is -0.37.
How many shares outstanding does Bolt Biotherapeutics, Inc. have?
Bolt Biotherapeutics, Inc. has 38,273,003 shares outstanding.
What happened to Bolt Biotherapeutics, Inc.’s price movement after its last earnings report?
Bolt Biotherapeutics, Inc. reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.34. Following the earnings report the stock price went down -3.125%.
Which hedge fund is a major shareholder of Bolt Biotherapeutics, Inc.?
Currently, no hedge funds are holding shares in BOLT
---
Company Description
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
---
Technical Analysis
ADC Therapeutics
―
Immatics
―
Foghorn Therapeutics
―
Cabaletta Bio
―
ALX Oncology Holdings
―
Kura Oncology
―
---